BioMarin Pharmaceuticals BMRN Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Vertex PharmaceuticalsVRTX

-$538.8M+20.8%

BiogenBIIB

——

Globus MedicalGMED

——

CytokineticsCYTK

——

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$766.2M+2.8%

Gross profit$571.2M-3.8%

Operating income$129.6M-42.1%

Net income$105.5M-43.2%

EPS (diluted)$0.54-43.2%

Balance sheet

See full

Cash & equivalents$3.1B+193%

Total debt$1.4B+138%

Total equity$6.2B+7.2%

Total assets$8.6B+20.2%

Cash flow

See full

Operating cash flow$220.7M+26.5%

CapEx$20.9M+24.8%

Free cash flow$199.7M+26.7%

Valuation

See full

Market cap$10.57B-19.4%

Enterprise value$8.93B-29.3%

P/E21.1×-22.7×

P/S3.3×-1.2×

Profitability

See full

Gross margin76.5%-2.9pp

Operating margin19.9%+7.2pp

Net margin16.8%+5.1pp

FCF margin23.7%+2.5pp

Returns & leverage

See full

Return on equity9.1%+2.8pp

Debt / equity0.2×+0.1×

Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioMarin Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?: BioMarin Pharmaceuticals (BMRN) reported cash provided by (used in) financing activity, including discontinued operation of $813.17M in Q1 2026.
How has BioMarin Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?: BioMarin Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation increased by 2196.9% year-over-year, from -$38.78M to $813.17M.